Androgen deprivation therapy added to radiation therapy (RT) for unfavorable-risk prostate cancer is not associated with an increased risk for cardiovascular mortality compared with RT alone, even among patients with preexisting cardiovascular disease, a study found.
In a small phase 2 trial involving men with intermediate-risk prostate cancer, a single ultra-high dose of radiation was safe and comparable to curative hypofractionated stereotactic body radiation therapy in tumor control and quality-of-life measures.
Robotic-assisted radical prostatectomy is associated with higher costs than open radical prostatectomy at the index hospitalization for the surgery, but it is associated with less healthcare use during the 1 year after discharge.
In a propensity score-based study, prostate cryoablation added to androgen deprivation therapy (ADT) improved failure-free survival and survival without castration-resistant disease compared with ADT alone.
The goal of the TRANSFORMER study was to compare the effects of bipolar androgen therapy with enzalutamide in asymptomatic men with castration-resistant prostate cancer who have experienced disease progression while receiving treatment with abiraterone.
Biparametric magnetic resonance imaging may offer advantages over PSA testing and ultrasonography by detecting more clinically significant prostate cancers without increasing the number of men advised to undergo prostate biopsies or overdiagnosed with clinically insignificant cancers.